Taltz (ixekizumab) and Zepbound (tirzepatide) - (TOGETHER-PsA)

Aug. 31, 2026: Eli Lilly and Company (NYSE: LLY) reported 52-week results from the open-label Phase 3b TOGETHER-PsO and TOGETHER-PsA trials of concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in adults with moderate-to-severe plaque psoriasis or active psoriatic arthritis, respectively, who also had obesity or overweight with at least one weight-related comorbidity.

In TOGETHER-PsO, the Week 52 primary composite endpoint of PASI 100 plus at least 10% weight loss was achieved by 30.6% with Taltz+Zepbound versus 4.4% with Taltz alone; PASI 100 was achieved by 40.5% versus 29.1%. In TOGETHER-PsA, the Week 52 primary composite endpoint of ACR50 plus at least 10% weight loss was achieved by 39.2% versus 1.7%; ACR50 was achieved by 43.7% versus 15.7%. Lilly said improvements in hsCRP and metabolic measures including BMI, blood pressure, glucose, HbA1c, triglycerides, and total cholesterol were sustained or further improved through one year.

No new safety concerns were identified; common adverse events in the combination arm (at least 5%) were nausea, diarrhea, constipation, injection-site reactions, vomiting, dizziness, and headache. The Week 52 analyses were pre-specified exploratory objectives without multiplicity control. Lilly said detailed 52-week results will be presented at future medical meetings and published in peer-reviewed journals.